Pharma heavyweights MSD (Merck) and Eisai have announced they are to join forces to develop and commercialise the latter’s tyrosine kinase inhibitor Lenvima (lenvatinib mesylate), both as a monotherapy and in combination with MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) in the treatment of a range of cancers.
Reageer